Cutaneous Oncology News

The FDA’s inaction approving sunscreen ingredients as well as studies about endocrine-disrupting chemicals in personal care products and Ozempic’s impact on hidradenitis suppurativa led Healio Dermatology’s most-read articles in September.

Skin cancer is the most prevalent cancer in the United States, with an estimated 97,610 new cases of invasive melanoma, 89,070 cases of in situ melanoma and about 7,990 deaths from the disease in 2023.

Leading dermatology organizations called on the U.S. surgeon general to continue its call to action to prevent skin cancer, the American Society for Dermatologic Surgery Association announced in a press release.

Cemiplimab provided clinically meaningful responses for patients with metastatic and locally advanced cutaneous squamous cell carcinoma, according to a study.

Researchers confirmed that head and neck melanomas have distinct biological characteristics that make it more adverse to patients yet more responsive to immunotherapy, according to a study.

Pembrolizumab significantly extended OS at 10 years compared with ipilimumab for patients with advanced melanoma, according to study results presented at ESMO Congress.

The addition of nivolumab to ipilimumab conferred a long-term OS benefit for patients with advanced melanoma, according to study results presented at ESMO Congress.

Celebrity news and nutrition stories led Healio Dermatology’s most-read articles in August.

A “simple model” known as ATLAS can help physicians detect recurrent cutaneous melanoma through symptom review, according to researchers.

The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection.